Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus interferon alfa-1b in unresectable stage IV melanoma
ChiCTR2000033712Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and recombinant human interferon alpha-1b in melanoma, sponsored by Xijing Hospital. Primary endpoints: Recommended phase II dose, Incidence and severity of adverse events and 2 more. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
toripalimabrecombinant human interferon alpha-1b
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2000033712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033712.